MDM2 SNP309 G allele decreases risk but does not affect onset age or survival of Chinese leukaemia patients

European Journal of Cancer

Volumn 44, Issue 5, 2008, Pages 760-766

  Phang, Beng Hooi ^a   Linn, Yeh Ching ^b   Li, Huihua ^a   Sabapathy, Kanaga ^a,c  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^b SINGAPORE GENERAL HOSPITAL   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Leukaemia; MDM2 SNP; p53 codon 72 SNP; Survival

Indexed keywords

ADULT; ARTICLE; CANCER PATIENT; CANCER RISK; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CODON; ETHNIC DIFFERENCE; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC TRANSCRIPTION; HUMAN; LEUKEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGE OF ONSET; ANTINEOPLASTIC AGENTS; CHINA; FEMALE; GENES, P53; GENOTYPE; HUMANS; LEUKEMIA; MALE; MIDDLE AGED; MUTATION; PILOT PROJECTS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS C-MDM2; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 40849112781     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2008.02.007     Document Type: Article

References (38)

1. Vousden K.H., and Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer 2 (2002) 594-604
2. Petitjean A., Achatz M.I., Borresen-Dale A.L., Hainaut P., and Olivier M. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene 26 (2007) 2157-2165
3. Wada M., Bartram C.R., Nakamura H., et al. Analysis of p53 mutations in a large series of lymphoid hematologic malignancies of childhood. Blood 82 (1993) 3163-3169
4. Harris S.L., Gil G., Robins H., et al. Detection of functional single-nucleotide polymorphisms that affect apoptosis. Proc Natl Acad Sci USA 102 (2005) 16297-16302
5. Bond G.L., and Levine A.J. A single nucleotide polymorphism in the p53 pathway interacts with gender, environmental stresses and tumour genetics to influence cancer in humans. Oncogene 26 (2007) 1317-1323
6. Watanabe T., Ichikawa A., Saito H., and Hotta T. Overexpression of the MDM2 oncogene in leukemia and lymphoma. Leuk Lymphoma 21 (1996) 391-397
7. Marks D.I., Kurz B.W., Link M.P., et al. Altered expression of p53 and mdm-2 proteins at diagnosis is associated with early treatment failure in childhood acute lymphoblastic leukaemia. J Clin Oncol 15 (1997) 1158-1162
8. Moller M.B., Nielsen O., and Pedersen N.T. Oncoprotein MDM2 overexpression is associated with poor prognosis in distinct non-Hodgkin's lymphoma entities. Mod Pathol 12 (1999) 1010-1016
9. Gustafsson B., Axelsson B., Gustafsson B., Christensson B., and Winiarski J. MDM2 and p53 in childhood cute lymphoblastic leukemia: higher expression in childhood leukemias with poor prognosis compared to long-term survivors. Pediatr Hematol Oncol 18 (2001) 497-508
10. Küpper M., Joos S., von Bonin F., et al. MDM2 gene amplification and lack of p53 point mutations in Hodgkin and Reed-Sternberg cells: results from single-cell polymerase chain reaction and molecular cytogenetic studies. Br J Haematol 112 (2001) 768-775
11. Koni{dotless}́ková E., and Kusenda J. Altered expression of p53 and MDM2 proteins in hematological malignancies. Neoplasma 50 (2003) 31-40
12. Hartmann E., Fernàndez V., Stoecklein H., Hernàndez L., Campo E., and Rosenwald A. Increased MDM2 expression is associated with inferior survival in mantle-cell lymphoma, but not related to the MDM2 SNP309. Haematologica 92 (2007) 574-575
13. Pietsch E.C., Humbey O., and Murphy M.E. Polymorphisms in the p53 pathway. Oncogene 25 (2006) 1602-1611
14. Dumont P., Leu J.L., Della PAC 3r., George D.L., and Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33 (2003) 357-365
15. Pim D., and Banks L. p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int J Cancer 108 (2004) 196-199
16. Siddique M., and Sabapathy K. Trp53-dependent DNA-repair is affected by the codon 72 polymorphism. Oncogene 25 (2006) 3489-3500
17. Papadakis E.N., Dokianakis D.N., and Spandidos D.A. p53 codon 72 polymorphism as a risk factor in the development of breast cancer. Mol Cell Biol Res Commun 3 (2000) 389-392
18. Koushik A., Platt R.W., and Franco E.L. p53 codon 72 polymorphism and cervical neoplasia: a meta-analysis review. Cancer Epidemiol Biomarkers Prev 13 (2004) 11-22
19. Khadang B., Fattahi M.J., Talei A., Dehaghani A.S., and Ghaderi A. Polymorphism of TP53 codon 72 showed no association with breast cancer in Iranian women. Cancer Genet Cytogenet 173 (2007) 38-42
20. Bergamaschi G., Merante S., Orlandi E., Galli A., Bernasconi P., and Cazzola M. TP53 codon 72 polymorphism in patients with chronic myeloid leukemia. Haematologica 89 (2004) 868-869
21. Kochethu G., Delgado J., Pepper C., et al. Two germ line polymorphisms of the tumour suppressor gene p53 may influence the biology of chronic lymphocytic leukemia. Leuk Res 30 (2006) 1113-1118
22. Zhang W., Hu G., and Deisseroth A. Polymorphism at codon 72 of the p53 gene in human acute myelogenous leukemia. Gene 117 (1992) 271-275
23. Nakano Y., Naoe T., Kiyoi H., et al. Poor clinical significance of p53 gene polymorphism in acute leukaemia. Leuk Res 24 (2000) 349-352
24. Sturm I., Bosanquet A.G., Hummel M., Dörken B., and Daniel P.T. In B-CLL, the codon 72 polymorphic variants of p53 are not related to drug resistance and disease prognosis. BMC Cancer 5 (2005) 105
25. Lahiri O., Harris S., Packham G., and Howell M. p53 pathway gene single nucleotide polymorphisms and chronic lymphocytic leukemia. Cancer Genet Cytogenet 179 (2007) 36-44
26. Bond G.L., Hu W., Bond E.E., et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumour suppressor pathway and accelerates tumour formation in humans. Cell 119 (2004) 591-602
27. Bond G.L., Hirshfield K.M., Kirchhoff T., et al. MDM2 SNP309 accelerates tumour formation in a gender-specific and hormone-dependent manner. Cancer Res 66 (2006) 5104-5110
28. Boersma B.J., Howe T.M., Goodman J.E., et al. Association of breast cancer outcome with status of p53 and MDM2 SNP309. J Natl Cancer Inst 98 (2006) 911-919
29. Campbell I.G., Eccles D.M., and Choong D.Y. No association of the MDM2 SNP309 polymorphism with risk of breast or ovarian cancer. Cancer Lett 240 (2006) 195-197
30. Petenkaya A., Bozkurt B., Akilli-Ozturk O., Kaya H.S., Gur-Dedeoglu B., and Yulug I.G. Lack of association between the MDM2-SNP309 polymorphism and breast cancer risk. Anticancer Res 26 (2006) 4975-4977
31. Ma H., Hu Z., Zhai X., et al. Polymorphisms in the MDM2 promoter and risk of breast cancer: a case-control analysis in a Chinese population. Carcinogenesis 240 (2006) 261-267
32. Swinney R.M., Hsu S.C., Hirshman B.A., Chen T.T., and Tomlinson G.E. MDM2 promoter variation and age of diagnosis of acute lymphoblastic leukemia. Leukemia 19 (2005) 1996-1998
33. Beckman G., Birgander R., Själander A., et al. Is p53 polymorphism maintained by natural selection?. Hum Hered 44 (1994) 266-270
34. Lum SS, Chua HW, Li HH, et al. MDM2 SNP309 G allele increases risk but the T allele is associated with earlier onset-age of breast cancers in the Chinese population. Carcinogenesis 2007 In press.
35. Siddique M.M., Balram C., Fiszer-Maliszewska L., et al. Evidence for selective expression of the p53 codon 72 polymorphs: implications in cancer development. Cancer Epidemiol Biomarkers Prev 14 9 (2005) 2245-2252
36. Thakkinstian A., McElduff P., D'Este C., and Attia J. A method for meta-analysis of molecular association studies. Statistics in Medicine 24 (2005) 1291-1306
37. Ganguli G., and Wasylyk B. p53-independent functions of MDM2. Mol Cancer Res 1 (2003) 1027-1035
38. Cheney MD, McKenzie PP, Volk EL, Fan L, Harris LC. MDM2 displays differential activities dependent upon the activation status of NFkappaB. Cancer Biol Ther 2007;8:7(1) Epub.